⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28007821 | 0.97 | — | — | |
| SCHEMBL8127892 | 0.81 | — | — | |
| Dimethylamine SCHEMBL3189287 | 0.78 | TDP1 (0.79) | — | |
| SCHEMBL14869541 | 0.76 | LMNA (0.40) | — | |
| SCHEMBL13157143 | 0.76 | TDP1 (0.48) | — | |
| SCHEMBL25571562 | 0.76 | TDP1 (0.48) | — | |
| SCHEMBL29020618 | 0.74 | — | — | |
| SCHEMBL31103 | 0.73 | — | — | |
| SCHEMBL14869036 | 0.72 | TDP1 (0.33) | — | |
| SCHEMBL9936913 | 0.71 | TDP1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114206870-B | Tricyclic AKR1C 3-dependent KARS inhibitors | 诺华股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-117642397-A | Modified proteins and protein binders | 上海睿跃生物科技有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20230365544-A1 | SMALL MOLECULE INHIBITORS OF CALCIUM CHANNEL ACTIVITY AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH | 2023-11-16 | — | — | US | disclosed |
| CN-116635380-A | PPARgamma modulators and methods of use | 卫材R&D管理有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-115403579-A | Novel spiro derivative and application thereof | 上海拓界生物医药科技有限公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-109153644-B | Small molecules against CEREBLON to enhance effector T cell function | H·李·莫菲特癌症中心研究有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-114206870-A | Tricyclic AKR1C3 dependent KARS inhibitors | 诺华股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-110003214-B | Substituted pyrazolo [1,5-a ] pyrimidine compounds as TRK kinase inhibitors | 阵列生物制药公司 | 2021-12-21 | — | — | CN | disclosed |
| CN-110177775-A | ROR gamma modulators and application thereof | 基恩菲特公司 | 2019-08-27 | — | — | CN | disclosed |
| CN-109153644-A | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H·李·莫菲特癌症中心研究有限公司 | 2019-01-04 | — | — | CN | disclosed |
| CN-1211373-C | 2,4-di (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2005-07-20 | — | — | CN | disclosed |
| WO-2005053688-A1 | SUBSTITUTED FURO[2,3-G] INDAZOLES FOR THE TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2005-06-16 | — | — | WO | disclosed |
| EP-1341754-B1 | SUBSTITUTED ANTHRANILIC ACIDS | AVENTIS PHARMA GMBH (DE) | 2004-12-08 | — | — | EP | disclosed |
| US-6649608-B2 | Cyclin-dependent serine/threonine and focal adhesion kinase inhibitors | ASTRAZENECA AB (SE) | 2003-11-18 | — | — | US | disclosed |
| EP-1341754-A1 | SUBSTITUTED ANTHRANILIC ACIDS | Aventis Pharma Deutschland GmbH (DE) | 2003-09-10 | — | — | EP | disclosed |
| CN-1406230-A | 2,4-di (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2003-03-26 | — | — | CN | disclosed |
| CN-1391562-A | Quinazoline derivatives as medicaments | ASTRAZENECA AB (SE) | 2003-01-15 | — | — | CN | disclosed |
| EP-1218354-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | AstraZeneca AB (SE) | 2002-07-03 | — | — | EP | disclosed |
| WO-2002046148-A1 | SUBSTITUTED ANTHRANILIC ACIDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-06-13 | — | — | WO | disclosed |
| WO-2001021596-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |